Oncology Corporate Profile
Eisai Inc. is a U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., a research-based human health care company that discovers, develops and markets products throughout the world. Eisai's human health care mission is to give first thoughts to patients and their families by developing drugs for diseases with significant unmet medical need. Nowhere is this more compelling than in oncology, one of Eisai's long-standing therapeutic areas of focus since 1987.
|Aloxi®||palonosetron hydrochloride||Aloxi® is a serotonin subtype 3 (5-HT3) receptor antagonist indicated for:|
• Moderately emetogenic cancer chemotherapy ' prevention of acute and delayed nausea and vomiting associated with initial and repeat courses
• Highly emetogenic cancer chemotherapy ' prevention of acute nausea and vomiting associated with initial and repeat courses
• Prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated
|Dacogen®||decitabine for Injection||Dacogen® is indicated for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and Intermediate-1, Intermediate-2, and High-Risk International Prognostic Scoring System groups.|
|Gliadel®||polifeprosan 20 with carmustine implant||Gliadel® is indicated in newly-diagnosed high-grade malignant glioma patients as an adjunct to surgery and radiation. Gliadel® is indicated in recurrent glioblastoma multiforme patients as an adjunct to surgery.|
|Halaven®||eribulin mesylate||Halaven® is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.|
|Hexalen®||altretamine capsules||Hexalen® (altretamine) capsules is indicated for use as a single agent in the palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agentbased combination.|
|Lenvima®||lenvatinib||Lenvima® (lenvatinib) is a prescription medicine used to treat people with differentiated thyroid cancer (DTC, a type of thyroid cancer) that can no longer be treated with radioactive iodine and is progressing.|
|Ontak®||denileukin diftitox||Ontak® is a CD25-directed cytotoxin indicated for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor.|
|Panretin®||alitretinoin gel 0.1%||Panretin® gel is indicated for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma. Panretin® gel is not indicated when systemic anti-KS therapy is required (e.g., more than 10 new KS lesions in the prior month, symptomatic lymphedema, symptomatic pulmonary KS, or symptomatic visceral involvement). There is no experience to date using Panretin® gel with systemic anti-KS treatment.|
|Salagen®||pilocarpine hydrochloride tablets||Salagen® Tablets are indicated for 1) the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck; and 2) the treatment of symptoms of dry mouth in patients with Sjogren's Syndrome.|
|Targretin®||bexarotene capsules||Targretin® (bexarotene) capsules are indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.|
|Targretin®||bexarotene gel 1%||Targretin® (bexarotene) gel 1% is indicated for the topical treatment of cutaneous lesions in patients with CTCL (Stage IA and IB) who have refractory or persistent disease after other therapies or who have not tolerated other therapies.|
View additional information on commercial products here »
|Brand / Product||Class||Area of Study||Phase||Partnership|
|farletuzumab / MORAb-003||IgG1 monoclonal antibody (humanized)||2nd line metastatic Ovarian cancer||III||Morphotek|
|Dacogen® / decitabine||antimetabolite (cytidine analog)||Acute Myelogenous Leukemia (AML)||III|
|Halaven® / eribulin mesylate / E7389||halichondrin B analog (synthetic)||1st line metastatic Breast cancer||III|
|Halaven® / eribulin mesylate / E7389||halichondrin B analog (synthetic)||2nd line metastatic Breast cancer||III|
|Halaven® / eribulin mesylate / E7389||halichondrin B analog (synthetic)||Non Small Cell Lung Cancer (NSCLC)||III|
|Halaven® / eribulin mesylate / E7389||halichondrin B analog (synthetic)||Sarcoma||III|
|Lenvima® / lenvatinib / E7080||multiple tyrosine kinase inhibitor||Hepatocellular carcinoma (HCC)||III|
|E7820 (+ cetuximab)||alpha2-integrin expression inhibitor||1st line metastatic Colorectal cancer||II|
|MORAb-004||IgG1 monoclonal antibody||1st line metastatic Melanoma||II||Morphotek|
|MORAb-009||IgG1 monoclonal antibody||1st line metastatic Pancreatic cancer||II||Morphotek|
|MORAb-004||IgG1 monoclonal antibody||Colorectal cancer||II|
|MORAb-009||IgG1 monoclonal antibody||Mesothelioma||II||Morphotek|
|farletuzumab (+ carboplatin and doxorubicin) / MORAb-003||IgG1 monoclonal antibody (humanized)||Non Small Cell Lung Cancer (NSCLC)||II|
|farletuzumab / MORAb-003||IgG1 monoclonal antibody (humanized)||Non Small Cell Lung Cancer (NSCLC)||II|
|farletuzumab (+ carboplatin and doxorubicin) / MORAb-003||IgG1 monoclonal antibody (humanized)||Platinum-sensitive Ovarian cancer||II||Morphotek|
|Halaven® / eribulin mesylate / E7389||halichondrin B analog (synthetic)||Prostate cancer||II|
|Lenvima® / lenvatinib / E7080||multiple tyrosine kinase inhibitor||Glioma||II|
|MORAb-028||IgG1 monoclonal antibody||1st line metastatic Melanoma||I||Morphotek|
|MORAb-004||IgG1 monoclonal antibody||1st line metastatic soft tissue Sarcoma||I||Morphotek|
|eribulin (+ PEGPH20 )||halichondrin B analog (synthetic)||Breast cancer||I||Halozyme|
|farletuzumab / MORAb-003||IgG1 monoclonal antibody (humanized)||Various cancer types||I||Morphotek|
|MORAb-009||IgG1 monoclonal antibody||Various cancer types||I||Morphotek|
|E7974||hemiasterlin analog (synthetic)||Various cancer types||I|
|MORAb-004||IgG1 monoclonal antibody||Various cancer types||I||Morphotek|
|E7820||alpha2-integrin expression inhibitor||Various cancer types||I|
|Halaven® / eribulin mesylate / E7389||halichondrin B analog (synthetic)||Bladder cancer||I|
|Lenvima® / lenvatinib / E7080||multiple tyrosine kinase inhibitor||2nd line metastatic Melanoma||I|
|Lenvima® / lenvatinib / E7080||multiple tyrosine kinase inhibitor||Renal cell carcinoma (RCC) Biomarker||I|
|MORAb-028||IgG1 monoclonal antibody||Various cancer types||Preclinical||Morphotek|
View additional information on product candidates here »
11/3/2016 11:42 am
(Reuters) Nov 2, 2016 - Cancer drugmakers are cutting prices to ensure their medicines are used routinely on Britain's National Health Service, following the overhaul of a cancer drug funding scheme, with Japan's Eisai the latest to win approval.
9/15/2016 12:05 pm
(PharmaTimes [UK]) Sept 15, 2016 - The European Commission has stamped its approval on the use of Eisai's Kisplyx to treat advanced kidney cancer.
9/6/2016 10:51 am
(pharmaphorum [UK]) Sept 5, 2016 - Eisai may have to sell its Halaven (eribulin) at rock-bottom prices in its new advanced liposarcoma use in Germany after a cost-effectiveness body found it offered “no additional benefit” compared with standard care.
8/9/2016 11:23 am
(Reuters) Aug 9, 2016 - Japan's Eisai Co said on Tuesday the U.S. Food and Drug Administration had confirmed that there was sufficient data to start Phase III studies of a drug it is co-developing to treat early Alzheimer's disease.
8/2/2016 11:15 am
(PharmaTimes [UK]) Aug 2, 2016 - Patients with an advanced form thyroid cancer may have to wait three years for NHS access to Eisai's Lenvima in England, after the drug was left out of the newly launched Cancer Drugs Fund.
7/26/2016 11:13 am
(Yahoo! Finance) July 26, 2016 - Halozyme Therapeutics, Inc. announced today that Eisai Inc. has dosed the first patient in a collaborative phase 1b/2 clinical trial to assess whether Eisai's eribulin mesylate (HALAVEN®) in combination with Halozyme's investigational drug PEGPH20 (PEGylated recombinant human hyaluronidase) can improve overall response rate (ORR) – the proportion of women that have a predefined reduction in tumor burden – as compared with eribulin alone as a therapy in women with advanced or metastatic, High-Hyaluronan (HA) HER2-negative breast cancer.
7/12/2016 07:19 am
(PharmaTimes [UK]) July 12, 2016 - Patients with thyroid cancer could be waiting three years for access to Eisai's Lenvima because the drug was left out of the re-launched Cancer Drugs Fund (CDF) and NICE guidance is not to be published until 2018.
7/8/2016 11:13 am
(Reuters) July 7, 2016 - Japan's Eisai said on Friday it would consider all options, including possible legal action, to fight delays in Britain's healthcare system that prevent patients from accessing one of its drugs to treat a rare form of cancer.
6/24/2016 01:00 pm
(EMA) June 24, 2016 - Orphan medicine Zalmoxis recommended by CAT and CHMP for marketing authorization.
5/18/2016 11:04 am
(UC San Diego Health) May 17, 2016 - Targeting both pathways with drug inhibitors more effective in stopping colorectal cancer growth.
5/16/2016 07:03 am
(Eisai) May 13, 2016 - Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) approved LENVIMA®(lenvatinib), the company's multiple receptor tyrosine kinase inhibitor, in combination with everolimus for the treatment of patients with advanced renal cell carcinoma (aRCC) who were previously treated with an anti-angiogenic therapy.
5/9/2016 11:04 am
(New York Times/Well blog) May 5, 2016 - “What is another year of your life worth?” Experts put the number at $50,000. Can patients like me — older people with recurrent disease — estimate the expense of a future year of cancer treatment to decide whether it’s worth it?
5/5/2016 11:35 am
(PharmaTimes [UK]) May 5, 2016 - Patients with a type of advanced tissue sarcoma called liposarcoma living in the European Union can now potentially get access to Eisai’s Halaven after regulators waved through the drug.
4/20/2016 12:30 pm
(Morningstar) Apr 20, 2016 - Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Avinash Desai, MD, as Vice President, Americas Oncology Medical Affairs for the Oncology Business Group (OBG).
4/19/2016 02:01 pm
(Washington Post/To Your Health) Apr 18, 2016 - It’s hard to overstate the hopes that are being pinned on this group of powerhouse scientists.
4/15/2016 11:01 am
(Medscape Medical News ) Apr 14, 2016 - Small gastrointestinal stromal tumors (GISTs) measuring less than 2 cm, although rare, might be more aggressive than previously thought, according to a study published online March 29 in the Journal of Gastrointestinal Surgery.
4/11/2016 11:03 am
(Washington Post/To Your Health) Apr 11, 2016 - You can avoid much of the financial havoc that cancer can cause. But you have to ask questions about money right from the start.
4/5/2016 07:07 am
(PharmaTimes [UK]) Apr 4, 2016 - Eisai’s breast cancer drug Halaven could soon be available in Europe to treat liposarcoma, after regulatory advisors backed expanding its use.
4/1/2016 11:27 am
(Pharmaceutical Business Review) Apr 1, 2016 - Eisai has signed an agreement to transfer the exclusive global development and commercialization rights, excluding Japan and Asia, to its cancer drug candidate E7777 to Dr. Reddy’s Laboratories.
3/31/2016 12:02 pm
(Wall Street Journal) Mar 30, 2016 - Pain treatment maker Centrexion Therapeutics, founded by former chief executives at Pfizer Inc. and Celgene Corp., agreed to acquire three new painkilling candidates from Germany’s Boehringer Ingelheim GmbH in a bid to expand its proprietary pipeline.
3/24/2016 11:01 am
(Morningstar) Mar 24, 2016 - Medivation, Inc. and Astellas Pharma Inc. today announced that the ARCHES (AR Inhibition with ChemoHormonal Therapy in Men with MEtastatic Castrate Sensitive Prostate Cancer) Phase III registrational trial, which will evaluate the efficacy and safety of enzalutamide with androgen deprivation therapy (ADT) versus placebo with ADT in metastatic hormone sensitive prostate cancer (mHSPC) patients, has been initiated and the first patient has been randomized.
3/22/2016 11:05 am
(Stanford Report) Mar 18, 2016 - A team of Stanford Bio-X scientists developed the first technique for viewing cells and tissues in three dimensions under the skin. The work could improve diagnosis and treatment for some forms of cancer and blindness.
3/18/2016 10:13 am
(StreetInsider) Mar 18, 2016 - Helsinn Therapeutics Inc. to obtain all rights to promote and distribute AKYNZEO® (netupitant/palonosetron); Eisai and Helsinn to continue to co-promote and distribute ALOXI® (palonosetron HCl) injection.
2/26/2016 12:02 pm
(European Pharmaceutical Review) Feb 26, 2016 - Eisai has strongly criticised NHS England (NHSE) for further delaying access to a number of new cancer treatments.
2/17/2016 12:09 pm
(FinanzNachrichten.de) Feb 17, 2016 - Eisai and PIQUR Therapeutics today announce a landmark agreement to conduct a Phase 1/2b clinical study to investigate PQR309 in combination with Halaven® (eribulin) in patients with triple-negative breast cancer (TNBC).
1/19/2016 11:43 am
(Pharmaceutical Business Review) Jan 19, 2016 - The US Food and Drug Administration (FDA) has granted priority review status to the supplemental new drug application (sNDA) submitted by Eisai for its anticancer agent lenvatinib mesylate to treat advanced or metastatic renal cell carcinoma.
1/19/2016 06:48 am
(Eisai) Jan 17, 2016 - Supplemental application based on progression-free survival data from Study 205, a three-arm Phase 2 study comparing lenvatinib in combination with everolimus, everolimus alone and lenvatinib alone in these patients; Agency granted lenvatinib Breakthrough Therapy designation for investigational indication in July 2015.
1/12/2016 12:03 pm
(PharmaTimes [UK]) Jan 12, 2016 - Eisai has submitted an application to market its oncology drug lenvatinib for the treatment of patients with renal cell carcinoma.
12/14/2015 11:47 am
(Pharmafile [UK]) Dec 11, 2015 - New data presented by Eisai supports the previously shown ability of Halaven (eribulin) to reverse epithelial-to-mesenchymal transition, the process by which cancerous cells are made more aggressive and harder to treat.
11/13/2015 12:33 pm
(Yahoo! Finance) Nov 13, 2015 - Helsinn Group and Eisai Inc. announced today that the American Society of Clinical Oncology (ASCO) has published a focused update to its clinical practice guidelines for antiemetics in oncology recognizing AKYNZEO® (netupitant/palonosetron) as an additional option for the prevention of acute and delayed nausea and vomiting in patients receiving highly-emetogenic chemotherapy regimens.
11/4/2015 12:17 pm
(Eisai) Nov 4, 2015 - Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it has initiated a research collaboration for research and development with the Paoli Calmettes Institute (IPC), a private non-profit comprehensive cancer center in Marseille, France, which has three missions: research, care and teaching.
10/19/2015 11:31 am
(Eisai) Oct 19, 2015 - Oct. 19, 2015 - Results from two national surveys of patients receiving chemotherapy and pharmacists, conducted by the Hematology/Oncology Pharmacy Association (HOPA) in collaboration with Eisai Inc.,* found that 83% of patients receiving chemotherapy who have experienced chemotherapy-induced nausea and vomiting (CINV) believe it is a side effect with which they must live.
9/14/2015 11:02 am
(ASCO in Action) Sept 11, 2015 - A foreword by ASCO President Julie M. Vose, MD, MBA, FASCO, discussing the need for big data utilization in advancing precision medicine was included in today's USA Today supplement on the future of cancer care.
8/11/2015 12:00 pm
(New York Times/Associated Press) Aug 11, 2015 - Barely 2 years old, Talia Pisano is getting tough treatment for kidney cancer that spread to her brain. She's also getting a chance at having babies of her own someday.
8/11/2015 11:05 am
(Yahoo! Finance) Aug 11, 2015 - Biocept, Inc. today announced a collaboration with the University of California, Irvine to evaluate biomarkers detected from blood-based versus invasive tissue biopsies in patients with metastatic cancers.
7/31/2015 11:55 am
(Yahoo! Finance) July 30, 2015 - Eisai Co., Ltd. and Halozyme Therapeutics, Inc. today sign a clinical collaboration agreement that will evaluate Halaven® (eribulin) in combination with Halozyme's investigational PEGPH20 (PEGylated recombinant human hyaluronidase) in first line HER2-negative metastatic breast cancer.
7/31/2015 11:54 am
(European Pharmaceutical Review) July 31, 2015 - Eisai has submitted regulatory applications in the United States, European Union and Japan for eribulin for the treatment of patients with inoperable soft tissue sarcoma (STS) who have received prior chemotherapy for advanced or metastatic disease.
7/24/2015 11:04 am
(Wall Street Journal/Pharmalot blog) July 23, 2015 - In the latest bid to alter the prescription-drug pricing landscape in the U.S., a new paper argues that the federal government could save between $15.2 billion and $16 billion annually if it negotiated with drug makers for Medicare Part D medicines and obtained the same prices that are paid by Medicaid or the Veterans Health Administration.
7/7/2015 12:00 pm
(ASCO) July 7, 2015 - Kevin Fitzpatrick has been named Chief Executive Officer (CEO) of CancerLinQ LLC, a wholly owned non-profit subsidiary of the American Society of Clinical Oncology (ASCO).
6/15/2015 12:02 pm
(PRWEB) June 15, 2015 - The Joint Clinical Trials Office of Weill Cornell Medical College and NewYork-Presbyterian Hospital has signed an agreement with Mytrus to develop a pilot project introducing e-Consent technology into the oncology clinics at NewYork-Presbyterian/Weill Cornell Medical Center.
6/12/2015 11:02 am
(Agios) June 12, 2015 - Agios Pharmaceuticals, Inc. today announced new data from the dose-escalation phase and expansion cohorts from the ongoing Phase 1 study evaluating single agent AG-221, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-2 (IDH2), in advanced hematologic malignancies.
5/31/2015 07:02 pm
(NPR Shots blog/KQED Public Radio) May 28, 2015 - Prices for common medical procedures vary widely, and it can be really hard to find out the true cost up front. This crowdsourcing project aims to help draw back the curtain on colonoscopy costs.
5/13/2015 12:01 pm
(Reuters) May 13, 2015 - Healthcare stocks may be unusually volatile after abstracts are released on Wednesday night by many companies scheduled to present at a cancer conference between May 29 and June 2.
5/4/2015 11:00 am
(RPCI) Apr 30, 2015 - Long-term and frequent use of aspirin is associated with significantly decreased risk of cervical cancer, according to a study led by researchers at Roswell Park Cancer Institute (RPCI) and published in the Journal of Lower Genital Tract Disease.
4/21/2015 01:02 pm
(New York Times) Apr 20, 2015 - A lawsuit claimed that Cephalon, a subsidiary of Teva Pharmaceuticals, had paid generic manufacturers to keep a cheaper version of a drug off the market.
4/6/2015 12:02 pm
(NCCN) Apr 6, 2015 - The NCCN Foundation®, which, through philanthropy empowers people through knowledge and advances the mission of the National Comprehensive Cancer Network® (NCCN®) to improve the quality, effectiveness, and efficiency of care provided to people with cancer, has awarded grants to six young investigators from NCCN Member Institutions.
4/6/2015 12:02 pm
(New York Times) Apr 6, 2015 - For years, doctors have faced draconian decreases in their reimbursements, but now Congress could solve this long-festering problem.
3/30/2015 12:00 pm
(MarketWatch) Mar 30, 2015 - Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has enrolled the first patient in a randomized, double-blind study of farletuzumab in first-relapsed, platinum-sensitive ovarian cancer with low levels of the immunosuppressive CA125 tumor antigen.
3/4/2015 12:00 pm
(Medscape Medical News) Mar 4, 2015 - For colorectal cancer screening, CT colonography (CTC) is more appealing than flexible sigmoidoscopy to men, but women do not appear to favor one strategy over the other.
2/26/2015 12:01 pm
(MD Anderson) Feb 25, 2015 - Patrick Hwu, M.D., chair of Melanoma Medical Oncology and Sarcoma Medical Oncology at The University of Texas MD Anderson Cancer Center, has been named division head of Cancer Medicine effective March 4.